{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:05:30Z","timestamp":1793304330992,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["NSERC"],"award-info":[{"award-number":["NSERC"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tier II Canada Research Chair in Lipids, Metabolism, and Health"},{"name":"Queen Elizabeth II Scholarship in Science and Technology"},{"name":"Canadian Institute of Health Research Scholarship \u2212 Masters"},{"name":"Ontario Graduate Scholarship and NSERC Post-Graduate Scholarship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.psyneuen.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T18:12:22Z","timestamp":1512756742000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Obesity exacerbates the acute metabolic side effects of olanzapine"],"prefix":"10.1016","volume":"88","author":[{"given":"Logan K.","family":"Townsend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem T.","family":"Peppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha D.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2017.12.004_bib0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","article-title":"Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis","volume":"16","author":"Albaugh","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0010","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1016\/j.psyneuen.2017.12.004_bib0020","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v60n0402","article-title":"The distribution of body mass index among individuals with and without schizophrenia","volume":"60","author":"Allison","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1467-789X.2011.00894.x","article-title":"The relevance of increased fat oxidation for body-weight management: metabolic inflexibility in the predisposition to weight gain","volume":"12","author":"Astrup","year":"2011","journal-title":"Obes. Rev."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tem.2014.07.004","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","author":"Ballon","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","volume":"48","author":"Boyda","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.psyneuen.2017.05.005","article-title":"Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia","volume":"82","author":"Castellani","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0065","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2337\/db08-0063","article-title":"Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients","volume":"57","author":"Ceriello","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.pnpbp.2007.11.013","article-title":"Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine","volume":"32","author":"Chen","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0075","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects","volume":"186","author":"Coccurello","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/jpet.108.137240","volume":"326","author":"Coccurello","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0100","first-page":"e55","article-title":"Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice","volume":"13","author":"Coccurello","year":"2008","journal-title":"Eat. Weight Disord."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","article-title":"30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice","volume":"29","author":"Coccurello","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0110","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2217\/pgs.15.55","article-title":"Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children","volume":"16","author":"Devlin","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0115","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.mp.4001729","article-title":"Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells","volume":"10","author":"Engl","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Fern\u00f8","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0125","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1001\/jama.2016.6458","article-title":"Trends in Obesity Among Adults in the United States, 2005\u20132014","volume":"315","author":"Flegal","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0130","doi-asserted-by":"crossref","first-page":"e12877","DOI":"10.14814\/phy2.12877","article-title":"Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance","volume":"4","author":"Frendo-Cumbo","year":"2016","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0135","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/diabetes.49.8.1367","article-title":"Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study","volume":"49","author":"Gastaldelli","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/372549a0","article-title":"Drug excretion mediated by a new prototype of polyspecific transporter","volume":"372","author":"Gr\u00fcndemann","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.euroneuro.2013.07.011","article-title":"Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model","volume":"24","author":"Hahn","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0155","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/dom.12148","article-title":"Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5\u2032-monophosphate-activated protein kinase","volume":"15","author":"Ikegami","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0160","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/schbul\/sbs196","article-title":"Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL\/6","volume":"40","author":"Klingerman","year":"2014","journal-title":"J mice. Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0170","first-page":"183","article-title":"Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors","volume":"25","author":"Laimer","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2539","article-title":"The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers","volume":"346","author":"Lawrence","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0180","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0185","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1249\/MSS.0000000000000660","article-title":"Adipose tissue insulin action and IL-6 signaling after exercise in obese mice","volume":"47","author":"MacPherson","year":"2015","journal-title":"Med. Sci. Sports Exer."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0190","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0195","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/jc.2003-031295","article-title":"Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity","volume":"89","author":"Muldoon","year":"2004","journal-title":"J. Clin. Endocrin. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.psyneuen.2017.12.004_bib0205","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0210","doi-asserted-by":"crossref","first-page":"R934","DOI":"10.1152\/ajpregu.00497.2015","article-title":"Voluntary wheel running attenuates lipopolysaccharide-induced liver inflammation in mice","volume":"310","author":"Peppler","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0220","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.9778\/cmajo.20140009","article-title":"Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study","volume":"2","author":"Pringsheim","year":"2014","journal-title":"CMAJ Open"},{"issue":"Suppl 1","key":"10.1016\/j.psyneuen.2017.12.004_bib0225","doi-asserted-by":"crossref","first-page":"M17","DOI":"10.1007\/s00125-002-0932-4","article-title":"Post-challenge hyperglycaemia is associated with premature death and macrovascular complications","volume":"46","author":"Qiao","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-15-0074","article-title":"Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance","volume":"227","author":"Remington","year":"2015","journal-title":"J. Endocrin."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","article-title":"Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology","volume":"101","author":"Rojo","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0240","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0245","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0250","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/JCP.0000000000000058","article-title":"Body mass index, obesity, and psychopathology in patients with schizophrenia","volume":"34","author":"Subramaniam","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2017.12.004_bib0260","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1124\/mol.51.6.913","article-title":"Cloning and functional expression of a human liver organic cation transporter","volume":"51","author":"Zhang","year":"1997","journal-title":"Mol. Pharmacol."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453017314026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453017314026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:59:08Z","timestamp":1759683548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453017314026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":52,"alternative-id":["S0306453017314026"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2017.12.004","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity exacerbates the acute metabolic side effects of olanzapine","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}